| 1 | 1/1 | 返回列表 |
| 查看: 404 | 回復: 0 | ||
iamlisheng木蟲 (小有名氣)
|
[求助]
藥代動力學(醫(yī)藥專業(yè))
|
|
12.3 Pharmacokinetics Absorption After single dose administration of REXULTI tablets, the peak plasma brexpiprazole concentrations occurred within 4 hours after administration; and the absolute oral bioavailability was 95%. Brexpiprazole steady-state concentrations were attained within 10-12 days of dosing. REXULTI can be administered with or without food. Administration of a 4 mg REXULTI tablet with a standard high fat meal did not significantly affect the Cmax or AUC of brexpiprazole. After single and multiple once daily dose administration, brexpiprazole exposure (Cmax and AUC) increased in proportion to the dose administered. In vitro studies of brexpiprazole did not indicate that brexpiprazole is a substrate of efflux transporters such as MDRI (P-gp) and BCRP. Distribution The volume of distribution of brexpiprazole following intravenous administration is high (1.56±0.42 L/kg), indicating extravascular distribution. Brexpiprazole is highly protein bound in plasma (greater than 99%) to serum albumin and a1-acid glycoprotein, and its protein binding is not affected by renal or hepatic impairment. Based on results of in vitro studies, brexpiprazole protein binding is not affected by warfarin, diazepam, or digitoxin. Elimination Metabolism Based on in vitro metabolism studies of brexpiprazole using recombinant human cytochrome P450 (CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4), the metabolism of brexpiprazole was shown to be mainly mediated by CYP3A4 and CYP2D6. In vivo brexpirazole is metabolized primarily by CYP3A4 and CYP2D6 enzymes. After single- and multiple-dose administrations, brexpiprazole and its major metabolite, DM-3411, were the predominant drug moieties in the systemic circulation. At steady-state, DM-3411 represented 23% to 48% of brexpiprazole exposure (AUC) in plasma. DM-3411 is considered not to contribute to the therapeutic effects of brexpiprazole. Based on in vitro data, brexpiprazole showed little to no inhibition of CYP450 isozymes. Excretion Following a single oral dose of [14C]-labeled brexpiprazole, approximately 25% and 46% of the administered radioactivity was recovered in the urine and feces, respectively. Less than 1% of unchanged brexpiprazole was excreted in the urine and approximately 14% of the oral dose was recovered unchanged in the feces. Apparent oral clearance of a brexpiprazole oral tablet after once daily administration is 19.8 (±11.4) mL/h/kg. After multiple once daily administration of REXULTI, the terminal elimination half-lives of brexpiprazole and its major metabolite, DM-3411, were 91 hours and 86 hours, respectively. |

| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 一志愿中國海洋大學,生物學,301分,求調劑 +5 | 1孫悟空 2026-03-17 | 6/300 |
|
|---|---|---|---|---|
|
[考研] 0856調劑,是學校就去 +6 | sllhht 2026-03-19 | 7/350 |
|
|
[考研] 一志愿南京理工大學085701資源與環(huán)境302分求調劑 +3 | 葵梓衛(wèi)隊 2026-03-18 | 5/250 |
|
|
[考研] 一志愿北京化工大學0703化學318分,有科研經歷,求調劑 +3 | 一瓶苯甲酸 2026-03-14 | 3/150 |
|
|
[考研] 一志愿西安交通大學材料工程專業(yè) 282分求調劑 +5 | 楓橋ZL 2026-03-18 | 7/350 |
|
|
[考研] 328求調劑,英語六級551,有科研經歷 +4 | 生物工程調劑 2026-03-16 | 12/600 |
|
|
[教師之家] 焦慮 +9 | 水冰月月野兔 2026-03-13 | 13/650 |
|
|
[考研] 0703化學 305求調劑 +4 | FY_yy 2026-03-14 | 4/200 |
|
|
[考研] 298-一志愿中國農業(yè)大學-求調劑 +7 | 手機用戶 2026-03-17 | 7/350 |
|
|
[考研] 一志愿西南交大,求調劑 +4 | 材化逐夢人 2026-03-18 | 4/200 |
|
|
[考研] 304求調劑 +12 | 小熊joy 2026-03-14 | 13/650 |
|
|
[考研] 材料,紡織,生物(0856、0710),化學招生啦 +3 | Eember. 2026-03-17 | 9/450 |
|
|
[考研] 301求調劑 +9 | yy要上岸呀 2026-03-17 | 9/450 |
|
|
[考研] 302求調劑 +4 | 小賈同學123 2026-03-15 | 8/400 |
|
|
[考研] 考研調劑 +3 | 淇ya_~ 2026-03-17 | 5/250 |
|
|
[考研] 0703 物理化學調劑 +3 | 我可以上岸的對?/a> 2026-03-13 | 5/250 |
|
|
[考研] 070305求調劑 +3 | mlpqaz03 2026-03-14 | 4/200 |
|
|
[考研] 中科大材料專碩319求調劑 +3 | 孟鑫材料 2026-03-13 | 3/150 |
|
|
[考研] 復試調劑 +3 | 呼呼?~+123456 2026-03-14 | 3/150 |
|
|
[考研] 招收0805(材料)調劑 +3 | 18595523086 2026-03-13 | 3/150 |
|